Differences

This shows you the differences between two versions of the page.

Link to this comparison view

cl:huntingtons-disease [on July 2, 2019]
cl:huntingtons-disease [on July 2, 2019]
Line 27: Line 27:
 </​WRAP>​ </​WRAP>​
 </​WRAP>​ </​WRAP>​
 +
 +===== Pathophysiology =====
 +The pathophysiology and neurochemical bases of Huntington'​s are poorly understood. Dopamine and glutamate transmission is hypothesized to be affected, leading to striatal and cortical changes resulting in motor dysfunction such as chorea.
  
 ===== Symptoms ===== ===== Symptoms =====
Line 48: Line 51:
 </​WRAP>​ </​WRAP>​
  
 +===== Treatment =====
 +==== Motor ====
 +Chorea is one of the core symptoms of Huntington'​s,​ and when there is significant motor dysfunction,​ this needs to be treated. Untreated chorea can worsen weight loss and increase falls risk. Tetrabenazine (up to 100 mg/day), amantadine (300–400 mg/day), or riluzole (200 mg/day) can be prescribed. Adverse effects such as depression, suicidality,​ parkinsonism (with tetrabenazine),​ and elevated liver enzymes (with riluzole) should be monitored for.
 + 
 +  * [[https://​www.ncbi.nlm.nih.gov/​pmc/​articles/​PMC3677041/​|Videnovic,​ A. (2013). Treatment of huntington disease. Current treatment options in neurology, 15(4), 424-438.]]
 +==== Psychiatric ====